Zydus Receives USFDA's Final Nod For Eletriptan Hydrobromide Tablets

Zydus Cadila has received the final approval from USFDA to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base), informed Cadila Healthcare on Monday.

The drug will be manufactured at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad. It is used in the treatment of migraine.

Meanwhile, Cadila Healthcare was trading higher by 1.4% at Rs 533 per share at 1044 hours IST on BSE. It hit a high of Rs 538.10 and a low of Rs 527.60 so far during the morning session.

The stock has delivered around 70% returns in a period of one year. It has outperformed both BSE Sensex and BSE Healthcare over a period of one year. Its closest peers are Lupin and Sun Pharmaceutical Industries.

Cadila Healthcare Limited, an integrated healthcare company, discovers, develops, manufactures, and markets a range of healthcare and pharmaceutical products worldwide.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.